| Ytd | 72.83% | |
| 1y | 92.66% |
| Open | 35.53 | Prev Close | 36.58 | Low | 35.26 | High | 36.13 | Mkt Cap | 711.20M |
| Vol | 9.44K | Avg Vol | 232.81K | EPS | -5.04 | P/E | N/A | Forward P/E | -4.85 |
| Beta | 1.70 | Short Ratio | 7.15 | Inst. Own | 110.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 35.74 | 200-d Avg | 25.86 | 1yr Est | 52.80 |
NGNE News
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers th
Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises t
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy a
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.53) per share which missed the analyst cons
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medici
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medici
47 total developmental milestones gained across 10 participants, with durable treatment effect and n
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy
Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to str
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.39) per share which missed the analyst cons
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers th
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.13) per share which met the analyst consens
U.S. stock futures lower, Dow futures down 1%. Yatsen Holding shares fall 10.1%, while other stocks
Canaccord Genuity analyst Whitney Ijem initiates coverage on Neurogene (NASDAQ:NGNE) with a Buy r
U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares
Autodesk Inc (ADSK) rose sharply after beating Q4 earnings & issuing strong guidance. Other gain
Neurogene stock jumps after FDA grants Breakthrough Therapy status to NGN-401 for Rett syndrome trea
LifeSci Capital analyst Patrick Dolezal initiates coverage on Neurogene (NASDAQ:NGNE) with a Outp
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy a
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medic
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty i
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy a
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy
Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollmentNew
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for ap
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys appro
Craig-Hallum analyst Albert Lowe initiates coverage on Neurogene (NASDAQ:NGNE) with a Buy rating
BMO Capital analyst Evan David Seigerman maintains Neurogene (NASDAQ:NGNE) with a Outperform and
